諾唯贊(688105.SH):擬在南京經開區投建南京諾唯贊生產基地項目
格隆匯12月29日丨諾唯贊(688105.SH)公佈,公司擬與南京經濟技術開發區管理委員會簽訂投資協議書,投資建設諾唯贊生產基地項目,總投資額約13億元。
公司根據公司戰略規劃落地及經營發展需要,擬與南京經濟技術開發區管理委員會簽署《諾唯贊生產基地投資協議書》,在南京經濟技術開發區投資建設南京諾唯贊生產基地項目。投資協議書約定總投資額約人民幣13億元,主要就一期項目投資建設內容進行約定。
本次生產基地項目投資實施主體為公司,包含全資子公司南京諾唯贊醫療科技有限公司及後續新設立的相關子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.